FDA Investigator Dina A Tallman

Dina A Tallman has conducted inspections on 42 sites in 8 countries as of 03 Jun 2024. See below for a list of the FDA enforcement documents resulting from those inspections.

Investigator Details

Number of Inspected Sites:
42
Last Inspection Date:
03 Jun 2024
Investigator Role:
FDA Investigator
Redica ID:
100001045
Countries of Inspections:
United States of America, Denmark, Bulgaria, India, Canada, Italy, Poland, Argentina
FDA Investigators that have inspected at least one site in common with Dina A Tallman:
Alanna L Mussawwir Bias, Alexandra B Pitkin, Andrace L Deyampert, Andrea A Branche, Andrea D Swingle, Anthony R Petriella, Barbara A Rusin, Bei Y He, Benjamin J Smith, Byron Ho, DVM, Byungja E Marciante, Carol Rivera Lopez, PhD, Catherine V Quinlan, Charles A Snipes, PhD, Charles I Ann, Charles L Zhou, Charles R Bonapace, PhD, Charles R Cote, RIC, Chase Bourke, PhD, Chelsea W Lamm, Constantin Y Philopoulos, Corey K Reno, Corrine M Carter, Daniel B Bordt, David A Paterson, Dawn C Olenjack, Debara R Reese, Debara Reese, Denise L Burosh, Dennis E Guilfoyle, PhD, Donald C Obenhuber, PhD, Douglas W Gronski, Dr. Gopa Biswas, PhD, Dr. Hansong Chen, PhD, Dr. Mark J Seaton, PhD, Dr. Zhou Chen (nmi), MD PhD, Dylan D Yao, MD, PhD, Emest F Bizjak, Emily J Orban, Eric S Myskowski, Eric S Pittman, Gajendiran Mahadevan, PhD, Gene R Gunn, Gregory W Smith, Habacuc V Barrera, Hyojong Kwon, PhD, Jasjeet K Sekhon, Jean Blackston Hill, Jeffrey A Sommers, Jeffrey D Meng, Jennifer A Kemp, Joseph A Piechocki, Joseph R Haynes, Joseph R Strelnik, Jyoti B Patel, PhD, Kara A Scheibner, PhD, Karen M Montgomery (KMM), Kellie L Thommes, RN, L'oreal F Walker, Larry K Austin, Laureen F Kononen, Lauren Iacono Connors, PhD, Lea Cranford, Leigh Anne Myers, Lisa M Bellows, Lisa P Oakes, Lloyd D Payne, Luella J Rossi, Margaret M Annes, Martin K Yau, PhD, Meisha R Sampson, Meisha Waters, Melina Lrodriguez Upton, Mercy Oyugi, Michael F Skelly, PhD, Michael Shanks, MS, Michele L Forster, PhD, Montgomery Montgomery, Karen M, Muna Algharibeh, Myra K Casey, Nailing Zhang, Nancy A Bellamy, Natalie A Mickelsen, DVM, Neali H Lucas, Niraj R Mehta, PhD, Patricia A Cochran, Patricia H Dlugosz, Patrick B Cummings, Patsy J Domingo, Qiao Y Bobo, Rafeeq A Habeeb, Raymond T Oji, Rebecca E Dombrowski, Robert D Tollefsen, Robert J Ham, Robert M Barbosa, Ronald R Ruff, Sandra A Boyd, Sandra A Hughes, Scott B Laufenberg, Sherri J Jackson, Sripal R Mada, PhD, Susan F Laska, MS, Susan P Bruederle, Suyang Qin, Terri E Gibson, Thomas J Arista, Thuy T Nguyen, LCDR, Tina M Pawlowski, Tracey Asinjen Wiersma, Victoria R Flournoy, Wayne E Seifert, William D Tingley, Xiaohan Cai, PhD, Xikui Chen (nmi), PhD, Yangmin Ning, Yumi J Hiramine

Dina A Tallman's Documents

Publish Date Document Type Title
April, 2023 FDA 483 Francis P. Worden, M.D. - Form 483, 2023-04-04
March, 2024 FDA 483 Northern Biomedical Research, Inc. - Form 483, 2024-03-29
July, 2021 FDA 483 Blair M. Brengle, M.D. - Form 483, 2021-07-08
September, 2023 FDA 483 Eli Lilly and Company - Form 483, 2023-09-15
August, 2023 FDA 483 Labcorp Early Development Laboratories, Inc. - Form 483, 2023-08-30
January, 2022 FDA 483 Donna S. Hrozencik, M.D. - Form 483, 2022-01-26
September, 2022 FDA 483 University Of Michigan - IRBMED - Form 483, 2022-09-02
October, 2022 FDA 483 Steven W. Pipe, M.D. - Form 483, 2022-10-24
October, 2022 FDA 483 Covance Cru Inc - Form 483, 2022-10-07
June, 2021 FDA 483 Moshe Talpaz, MD - Form 483, 2021-06-17
May, 2023 FDA 483 Suresh Anne, M.D. - Form 483, 2023-05-19
January, 2022 EIR Donna S. Hrozencik, M.D. - EIR, 2022-01-26
January, 2023 FDA 483 Robert M. Pascuzzi, M.D. - Form 483, 2023-01-27
July, 2021 EIR Charles River Laboratories - EIR, 2021-07-16
July, 2023 FDA 483 Indira Brar, M.D. - Form 483, 2023-07-28
April, 2024 FDA 483 Liana Apostolova, M.D. - Form 483, 2024-04-18
March, 2024 FDA 483 Sagar Parikh, M.D. - Form 483, 2024-03-08
August, 2024 FDA 483 Shirish M. Gadgeel, MD - Form 483, 2024-08-23
July, 2024 FDA 483 Labcorp Early Development Laboratories Inc. - Form 483, 2024-07-12
September, 2024 FDA 483 Randy D. Hicks, M.D. - Form 483, 2024-09-12

Experience Redica Systems’ NEW investigator profiles and dashboards

Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:

  • Total inspections conducted
  • 483 rate
  • OAI rate
  • Warning Letter rate
  • Inspections by Industry, Scope, and Inspection Reason
  • And much more

Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.

FDA Investigator Profile Icon

Talk to sales to access our investigator profiles

Loading...

Investigator Profiles Are Just the Tip of the Iceberg

Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:

Inspection Intelligence

  • Pre-Approval Inspection (PAI) trends
  • The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
  • Latest 483s: see what the trends are across all FDA Investigators
  • CFR Heatmap: Citations aggregated by Subpart by Year

Vendor Intelligence

  • Full inspection histories for your vendors down to the specific site level
  • All of the functionality mentioned above but isolated to just your vendors

Regulatory Intelligence

  • Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
  • All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more